Open Government Portal
1.1 The purposes of this Notice are:
a. To inform importers of the Ministers policies and practices respecting the administration …
Health Canada carried out this safety review when it became aware that the FDA was investigating the risk of angle-closure …
Health Canada reviewed the potential risk of DRESS with the use of atypical antipsychotics, following the manufacturers’ voluntary update of …
Health Canada carried out a safety review to look into the risk of sleep apnoea with the use of atypical …
Health Canada reviewed the potential risk of SW and SRED with the use of atypical antipsychotics, following the publication of …
Health Canada carried out a safety review to look into the use of atypical antipsychotics and the potential risk of …
Health Canada reviewed the potential risk of colitis with Aubagio use after finding reports (since being marketed) of colitis as …
The Canadian product safety information for lorazepam and midazolam warn that they should not be used during pregnancy. The Canadian …
Health Canada reviewed the potential risk of severe bone damage (osteonecrosis) with bisphosphonate use because of product information updates in …
Health Canada has completed a safety review on the potential risk of BIA-ALCL, following an increase in the number of …